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Background: Previous aztreonam for inhalation solution (AZLI) studies included patients with cystic fibrosis, Pseudomonas aeruginosa (PA)
airway infection, and forced expiratory volume in 1 s (FEV1) 25% to 75% predicted. This double-blind, multicenter, randomized, placebo-
controlled trial enrolled patients (≥6 years) with FEV1N75% predicted.
Methods: AZLI 75 mg (n=76) or placebo (n=81) was administered 3-times daily for 28 days with a 14-day follow-up.
Results: Day 28 treatment effects were 1.8 points for CFQ-R-Respiratory Symptoms Scale (95%CI: −2.8, 6.4; p=0.443; primary endpoint); −1.2
for log10 sputum PA colony-forming units (p=0.016; favoring AZLI), and 2.7% for relative FEV1% predicted (p=0.021; favoring AZLI).
Treatment effects favoring AZLI were larger for patients with baseline FEV1 b90% predicted compared to ≥90% predicted. AZLI was well-
tolerated.
Conclusions: Effects on respiratory symptoms were modest; however, FEV1 improvements and bacterial density reductions support a possible role
for AZLI in these relatively healthy patients. ClinicalTrials.gov identifier: NCT00712166.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Aztreonam; Cystic fibrosis; Respiratory symptoms; Inhaled antibiotics; Pseudomonas1. Introduction
Cystic fibrosis (CF) is an autosomal-recessive disease
characterized by thick pulmonary secretions and chronic airway
infection with difficult to treat pathogens, the most significant of
which is Pseudomonas aeruginosa (PA) [1]. The prevalence of
infection increases with age; in 2008, 39.2% of US patients☆ The study data have been previously presented at the 33rd European Cystic Fib
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doi:10.1016/j.jcf.2011.02.007b18 years and 73.6% of patients ≥18 years of age were PA-
positive [2]. Chronic airway infection is associated with pro-
gressive loss of lung function, which is the primary cause of
death for CF patients [2,3].
Alternate-month, suppressive therapy with inhaled antibio-
tics is standard of care for CF patients infected with PA [4,5].
Evidence for this practice came from studies of patients withrosis Conference, held 16–19 June 2010 in Valencia, Spain.
d by Elsevier B.V. All rights reserved.
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available inhaled antibiotics in the US are approved for patients
with CF and FEV1 25%–75% predicted, as these were the entry
criteria for registration trials. Since the goal of such therapy is to
preserve lung function and patients with high baseline lung
function have a greater risk of steeper decline in lung function,
CF patients with PA airway infection and normal to mildly
compromised lung function should also benefit [6]. The
prevalence of patients with mildly compromised lung function
is increasing; in 2008, 56.6% of CF patients b18 years of age
had FEV1N90% predicted [2].
This study evaluated an inhaled antipseudomonal antibiotic,
aztreonam for inhalation solution (AZLI; Cayston®, Gilead
Sciences, Inc., Foster City CA). AZLI is indicated to improve
respiratory symptoms in CF patients with PA [7]. Previous
AZLI studies included patients with moderately to severely
impaired lung function (FEV1 25%–75% predicted) and
showed significant improvements relative to placebo on the
Cystic Fibrosis Questionnaire—Revised (CFQ-R) Respiratory
Symptoms Scale (RSS), time-to-need for intravenous (IV) or
additional inhaled antipseudomonal antibiotics, forced expira-
tory volume in 1 s (FEV1), and log10 PA colony forming units
(CFUs) in sputum [8–11]. The current study repeats a previous
study design (AIR-CF1), extending the efficacy and safety
evaluation of AZLI to include patients with CF, PA airway
infection, and milder impairment of lung function (FEV1N75%
predicted) [9,12].
2. Materials and methods
2.1. Study design
This double-blind, multicenter, multinational, randomized,
placebo-controlled trial was conducted from June 2008 to June
2009 at 40 CF centers (US: 34; Canada: 1; Australia: 5).
Eligibility was assessed at screening, ≤14 days before baseline
(Day 0). Patients were randomly assigned (1:1) to a 28-day
course of AZLI or placebo, administered three times daily
(TID), with doses separated by ≥4 h. Randomization was
stratified by age (6–13, 14–17, ≥18 years) and geographic
region (North America, Australia; randomization code gener-
ated by Gilead Sciences). Additional study visits were at Day 14
(mid-treatment), Day 28 (end-of-treatment), and Day 42
(follow-up).
A physical examination was performed at screening. Post-
bronchodilator spirometry was performed according to Amer-
ican Thoracic Society guidelines at each study visit [13].
FEV1% predicted was calculated using the Knudson equation
[14].
AZLI (75 mg aztreonam, 52.5 mg lysine monohydrate) and
placebo (5 mg lactose, 7.3 mg NaCl) were diluted in 0.17%
saline (1 mL) and self-administered with the investigational
eFlow® electronic nebulizer (PARI GmbH, Starnberg,
Germany). Patients self-administered a short acting bronchodi-
lator before each study drug dose.
This study was conducted in compliance with the protocol,
the Declaration of Helsinki, the International Conference onHarmonisation guideline for Good Clinical Practices, all
applicable US Food and Drug Administration regulations,
Canadian Health Products and Food Branch regulations,
Australian Therapeutic Goods Administration regulations, and
all other applicable local laws and regulations. Institutional
review boards or ethics committees approved the study for each
site. Patients and/or their legal representatives/guardians
provided informed consent, or assent as applicable, before
any study-related procedures, including screening procedures,
were performed.
2.2. Study population
Eligible patients were ≥6 years of age, with documented CF
and FEV1N75% predicted at screening. PA was present in
expectorated sputum or throat swab culture samples at screen-
ing or documented in 2 samples within previous 12 months (1
positive sample obtained≤3 months before screening). Eligible
patients had experienced ≥2 of the following chronic and/or
intermittent CF symptoms for≥28 days before baseline with no
worsening of symptoms within 7 days before baseline: chest
congestion, daily cough, productive cough, wheezing, trouble
breathing, or nocturnal wakening due to coughing. Eligible
patients did not require immediate antipseudomonal antibiotic
treatment of an impending exacerbation; investigators consid-
ered them to be in a stable condition. Patients were able to
perform reproducible pulmonary function tests.
Exclusion criteria included known hypersensitivity to
monobactam antibiotics, inability to tolerate short-acting
bronchodilators, lung transplantation history, or previous
enrollment in an AZLI trial. Changes in baseline medications
(azithromycin, hypertonic saline, or dornase alpha) or admin-
istration of any antipseudomonal antibiotic within 28 days
before screening were excluded, as were changes in antimicro-
bial, bronchodilator, or corticosteroid medications or physio-
therapy technique or schedule within 7 days before screening.
Patients had a chest radiograph within 180 days before
screening, with no significant acute findings (e.g., lobar
infiltrate and atelectasis, pneumothorax, or pleural effusion).
Females of child-bearing potential had a negative urine
pregnancy test at screening, were practicing an acceptable
method of birth control, and were not lactating. Patients who
had received any investigational drug or device within 28 days
(or 6-half lives) before screening were excluded, as were
patients with any serious or active medical or psychiatric illness,
which in the opinion of the investigator, would interfere with
patient treatment, assessment, or compliance with the protocol.
2.3. Study endpoints
The primary efficacy endpoint was change from baseline at
Day 28 on the CFQ-R RSS [11]. CFQ-R domains and scales are
scored from 0 to 100, with higher scores indicating fewer
symptoms, better functioning, or higher health-related quality of
life. Secondary endpoints were: change from baseline at Days
14 and 42 on the CFQ-R RSS, change from baseline at Day 28
on the CFQ-R Physical Functioning Scale, use of additional
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ized, and change from baseline at Day 28 for log10 PA CFUs in
sputum and FEV1% predicted. Additional efficacy endpoints
included changes in other pulmonary function measures,
weight, body mass index (BMI), other CFQ-R scores, and
number of hospitalization days or missed school/work days.
Safety endpoints included adverse events, acute airway
reactivity, vital signs, serum chemistry, and hematology.
Microbiological endpoints included the disappearance or
appearance of respiratory pathogens and the change in
minimum inhibitory concentration (MIC) of aztreonam for
PA. The aztreonam concentrations required to inhibit the growth
of 50% or 90% of PA isolates were reported as MIC50 or MIC90
values, respectively.
2.4. Statistical methods
Analyses included all randomly-assigned patients receiving
≥1 dose of study drug. Statistical tests were 2-tailed superiority
analyses (α=0.05). Spirometry changes were calculated as
relative values, calculated as a percentage of the baseline
measurement. Microbiology assessments did not include data
from all patients; some patients were not able to expectorate
sputum samples, and some were PA-positive but CFUs were not
reported.
Based on the results from a previous AZLI study, a sample
size of 140 patients provided ≥90% power to detect a 10-point
difference between groups in mean change from baseline at Day
28 on the CFQ-R RSS, using a 2-sided 0.05-level test and
assuming a standard deviation of 17.5 [9].
For the primary efficacy analysis, treatment effect was
assessed by a parametric analysis of covariance (ANCOVA);
treatment and age group were fixed effects and baseline CFQ-R
RSS score was a covariate. Analyses of other continuous
variables used similar ANCOVA models, with respective
baseline values as covariates. Exploratory analyses were
performed for patients in mild (FEV1N75 to b90% predicted)
and normal (FEV1≥90% predicted) lung function categories asScreened:  192
Did not satisfy all inclusion a
Withdrew consent:  4
Randomly assigned:  160
Treated: 157 (ITT populatio
Not treated: 3
Patient request:  1
Protocol violation:  2
Placebo:  81
Completed study:  81
Completed treatment:  79
Did not complete treatment:  2
Adverse event:  1
Discontinued study:  0
Fig. 1. Patient destablished by the Cystic Fibrosis Foundation (CFF), except the
CFF “mild” category extends to 70% predicted [2].
3. Results
A total of 192 patients were screened and 157 patients
received study-drug treatment (Fig. 1). Most patients
used≥80% of study-drug doses (AZLI: 85.5% patients;
placebo: 92.6%). One patient (AZLI) discontinued from the
study and 6 patients discontinued treatment but remained in the
study, discontinuing treatment was associated with pulmonary
exacerbation for 3 patients (AZLI: 2; placebo: 1) and with the
adverse event of FEV1 decreased for 1 patient (AZLI).
Demographic characteristics were well balanced between
treatment arms (Table 1). The majority of patients were 6–
17 years of age (56.7%). Most patients were receiving dornase
alfa (81.5%) and pancreatic enzymes (88.5%) at baseline.
Patients had received a mean of 2.9 courses of TIS in the
previous year; 65.0% of patients had received≥1 course.
3.1. Efficacy
Adjusted mean change at Day 28 from baseline CFQ-R RSS
scores was 3.22 for AZLI-treated and 1.41 for placebo-treated
patients (Table 2A; Fig. 2). The treatment effect (1.80; 95%
confidence interval [CI]: −2.83, 6.44) was not statistically
significant (p=0.443). Thus this study did not meet the primary
efficacy endpoint. Subgroup analyses were performed for a pre-
selected group of variables. Larger treatment effects were obser-
ved in favor of AZLI in female and adult patients, although these
treatment effects were not statistically significant (Table 2A).
Statistically significant treatment effects favoring AZLI were
observed for several secondary efficacy endpoints: change from
baseline at Day 28 for adjusted mean log10 PA CFUs in sputum
(AZLI: −1.4; placebo: −0.14; p=0.016) and adjusted mean
relative change in FEV1% predicted (AZLI: 0.29%; placebo:
−2.5%; p=0.021; Table 2A; Fig. 2). Amongst other efficacy
endpoints, significant treatment effects favoring AZLI werend exclusion criteria:  28
n)
AZLI:  76
Completed study: 75
Completed treatment:  71
Did not complete treatment:  4
Adverse event:  3
Discontinued study:  1
Patient noncompliance with protocol:  1
isposition.
Table 1
Baseline demographic and clinical characteristics.
Placebo
N=81
AZLI
N=76
Total
N=157
Region; n (%)
North America 75 (92.6) 72 (94.7) 147 (93.6)
Canada 2 (2.5) 0 2 (1.3)
United States 73 (90.1) 72 (94.7) 145 (92.4)
Australia 6 (7.4) 4 (5.3) 10 (6.4)
Age, years; mean (SD) 18.9 (9.1) 19.5 (9.1) 19.2 (9.1)
Age group; n (%)
6 to 13 years 25 (30.9) 22 (28.9) 47 (29.9)
14 to 17 years 22 (27.2) 20 (26.3) 42 (26.8)
≥18 years 34 (42.0) 34 (44.7) 68 (43.3)
6 to 17 years 47 (58.0) 42 (55.3) 89 (56.7)
Male gender; n (%) 44 (54.3) 46 (60.5) 90 (57.3)
White race; n (%) 77 (95.1) 74 (97.4) 151 (96.2)
Weight, kg; mean (SD) 53.5 (14.6) 57.9 (17.8) 55.6 (16.3)
Body mass index, kg/m2; mean (SD) 20.7 (3.0) 21.7 (4.2) 21.2 (3.7)
CFTR genotype a; n (%)
Homozygous for Δ508 40 (57.1) 39 (54.2) 79 (55.6)
Heterozygous for Δ508 26 (37.1) 23 (31.9) 49 (34.5)
Unidentified 2 (2.9) 9 (12.5) 11 (7.7)
Other 2 (2.9) 1 (1.4) 3 (2.1)
TIS courses in previous year; mean (SD) 3.0 (2.7) 2.9 (2.5) 2.9 (2.6)
Use of medications at baseline; n (%)
Azithromycin 48 (59.3) 41 (53.9) 89 (56.7)
Dornase alfa 65 (80.2) 63 (82.9) 128 (81.5)
Pancrelipase 69 (85.2) 70 (92.1) 139 (88.5)
Salbutamol 54 (66.7) 48 (63.2) 102 (65.0)
Baseline values; mean (SD)
FEV1% predicted 94.7 (12.9) 95.5 (12.7) 95.1 (12.8)
FEV1 (L) 2.9 (0.8) 3.1 (0.9) 3.0 (0.9)
Log10 PA CFUs in sputum
b 4.4 (3.1) 4.8 (2.6) 4.6 (2.9)
CFQ-R Respiratory Symptoms Score 73.6 (17.9) 70.3 (18.5) 72.0 (18.2)
MIC of aztreonam for all PA isolates at baseline
MIC50; μg/mL ≤1 ≤1 ≤1
MIC90; μg/mL 16 8 8
Minimum MIC; μg/mL ≤1 ≤1 ≤1
Maximum MIC; μg/mL 128 128 128
No. isolates tested c 104 104 208
Highest MIC c; n (%)
≤8 μg/mL 53 (84.1) 58 (90.6) 111 (87.4)
N8 μg/mL 10 (15.9) 6 (9.4) 16 (12.6)
a No. of patients with data=70 (placebo), 72 (AZLI), and 142 (total).
b No. of patients with data=43 (placebo), 47 (AZLI), and 90 (total).
c No. of patients with data=63 (placebo), 64 (AZLI), and 127 (total) CFTR=cystic fibrosis transmembrane conductance regulator; CFQ-R=Cystic Fibrosis
Questionnaire—Revised; CFUs=colony forming units; FEV1=forced expiratory volume in 1 s; MIC=minimum inhibitory concentration; PA=P. aeruginosa.
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Day 28 and CFQ-R Social Functioning scores (Table 2B). Use
of oral, IV, or additional inhaled antibiotics was similar for the
AZLI (n=19) and placebo (n=21) groups during the entire
study, with most use occurring during the follow-up period for
both treatment groups (AZLI: 15; placebo: 17).
This study enrolled patients with mild disease severity
(FEV1N75% predicted). Using the CFF's established lung
function categories, the disease severity category was sub-
divided into “mild” (FEV1N75 to b90% predicted at baseline,
39.5% patients, n=62/157), and “normal” (FEV1≥90%
predicted at baseline, 60.5% patients, n=95/157), and patient
characteristics and efficacy responses were characterized in an
exploratory analysis. Patients with mild lung function impair-ment (FEV1N75 to b90% predicted) at baseline were older
(mean [SD] age=20.7 [8.8] vs. 18.2 [9.1] years), with lower
baseline scores on the CFQ-R RSS (67.4 [19.7] vs. 75.2 [16.5])
and higher baseline log10 PA sputum CFUs (5.30 [2.50] vs. 4.00
[3.01]), compared to patients with normal lung function
(baseline FEV1≥90% predicted). AZLI vs. placebo treatment
effects for scores on the CFQ-R RSS were larger at Day 28 for
patients with baseline FEV1b90% predicted than for patients
with baseline FEV1≥90% predicted (Table 2A). Likewise,
AZLI vs. placebo treatment effects for mean relative change in
FEV1% predicted were larger at Day 28 for patients with
baseline FEV1b90% predicted (4.8% treatment effect;
p=0.032) than for patients with baseline FEV1≥90% predicted
(1.4% treatment effect, p=0.302).
Table 2A
Efficacy results: primary and secondary endpoints.
Placebo (N=81) AZLI (N=76) Treatment
effect e
P-value f
Adjusted mean change from baseline to Day 28 (SE)
No. No.
Primary efficacy endpoint a
CFQ-R Respiratory Symptoms Score 81 1.4 (1.6) 75 3.2 (1.7) 1.8 0.443
Subgroup analyses a
Region
North America 75 2.0 (1.7) 71 3.5 (1.8) 1.4 0.562
Australia 6 −4.0 (5.4) 4 −0.88 (6.7) 3.2 0.725
Age group
6–13 years 25 0.85 (3.4) 22 1.3 (3.6) 0.45 0.927
14–17 years 21 3.4 (2.7) 19 1.3 (2.8) −2.1 0.593
≥18 years 34 0.44 (2.4) 34 5.1 (2.4) 4.7 0.183
6–17 years 46 1.8 (2.2) 41 1.5 (2.4) −0.23 0.942
Gender
Male 44 3.7 (2.3) 45 3.7 (2.3) −0.04 0.990
Female 37 −1.2 (2.4) 30 2.7 (2.6) 3.9 0.273
CFQ-R version
Child 26 −3.0 (8.7) 22 −2.6 (9.4) 0.45 0.927
Adolescent/adult 55 1.8 (1.8) 53 4.0 (1.9) 2.3 0.385
Highest aztreonam MIC for PA b
≤8 μg/mL 53 0.83 (2.3) 57 3.1 (2.1) 2.2 0.463
N8 μg/mL 10 −2.1 (4.1) 6 10.5 (5.3) 12.6 0.103
FEV1 at baseline
c
b90% predicted 33 2.7 (2.7) 29 9.5 (2.7) 6.7 0.072
≥90% predicted 48 0.55 (2.1) 46 −0.81 (2.2) −1.4 0.658
Secondary efficacy endpoints
CFQ-R Respiratory Symptoms Score (baseline to Day 14) a 81 0.28 (1.6) 75 3.7 (1.6) 3.4 0.133
CFQ-R Respiratory Symptoms Score (baseline to Day 42) a 81 2.9 (1.7) 75 3.0 (1.7) 0.10 0.965
CFQ-R Physical Functioning Score (baseline to Day 28) a 80 −0.69 (1.5) 76 1.8 (1.6) 2.5 0.256
Log10 PA CFUs in sputum (baseline to Day 28) 31 −0.14 (0.36) 37 −1.4 (0.36) −1.2 0.016
Relative change in FEV1% predicted (baseline to Day 28)
a 81 −2.5 (0.82) 76 0.29 (0.85) 2.7 0.021
n (%); Baseline to End of Study P-value g
Use of Oral, IV, or Additional Inhaled
Antipseudomonal Antibiotics
21 (25.9) 19 (25.0) N0.999
Number of Patients Hospitalized d 3 (3.7) 8 (10.5) 0.122
CFQ-R=Cystic Fibrosis Questionnaire—Revised; CFUs=colony forming units; FEV1=forced expiratory volume in 1 s; IV=intravenous; MIC=minimum inhibitory
concentration; PA=P. aeruginosa.
a Missing postbaseline data were imputed with the last observation carried forward (LOCF) method.
b The parenteral breakpoint for aztreonam is 8 μg/mL.
c Exploratory analysis.
d Two additional patients (AZLI: 1, placebo: 1) were hospitalized off-study, each on Day 55, for pulmonary exacerbation.
e AZLI — placebo.
f ANCOVA analyses. ANCOVA models included treatment, age group, and baseline values. Models for age subgroups included treatment and baseline values.
g Fisher's Exact Test.
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The majority of patients experienced one or more adverse
events during the study (AZLI: 77.6%, n=59/76; placebo:
76.5%, n=62/81). Adverse events were mild to moderate in
severity for most of these patients (AZLI: 91.5%, n=54/59;
placebo: 95.2%, n=59/62). Cough and productive cough were
the most commonly reported adverse events (Table 3). The
incidence of the most commonly reported adverse events was
similar for both treatment groups, except abdominal pain was
reported for significantly fewer AZLI-treated patients. The most
commonly reported adverse events considered by investigators
to be treatment-related were cough (AZLI: 9.2%; placebo:
4.9%), productive cough (3.9%; 3.7%), respiratory tractcongestion (3.9%; 0%), and pulmonary function test decreased
(0%; 3.7%). Serious adverse events were reported for 11.8%
(n=9/76) of AZLI-treated and 3.7% (n=3/81) of placebo-
treated patients (p=0.073). These 12 patients experienced 20
serious adverse events; all were associated with hospitalizations
and none were considered by investigators as treatment-related.
The 12 on-study hospitalizations of 11 patients were associated
with pulmonary exacerbation (AZLI: 2; placebo: 2); bronchitis,
bronchiectasis, or bronchopneumonia (AZLI: 3), gastrointesti-
nal conditions (AZLI: 2; placebo: 1), fever (placebo: 1), and
influenza (AZLI: 1). No patients experienced an acute decrease
in FEV1 of ≥15% after dosing at clinic visits and there were no
reports of anaphylaxis. There were no significant differences
between AZLI and placebo groups in clinical chemistry or
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cell, neutrophil, and platelet counts above the normal reference
ranges were observed for fewer AZLI-treated patients. There
were no deaths in this study.
3.3. Microbiology
Sputum samples were positive for PA for 86.5% of AZLI-
treated patients at baseline (n=64/74); this decreased to 66.2%
of patients at Day 28 (n=49/74) and increased to near baseline
values at Day 42 (80.0%, n=60/75). The prevalence of PA-
positive placebo-treated patients showed little change (baseline:
84.0%, n=63/75; Day 28: 83.5%, n=66/79; Day 42: 82.7%,
n=62/75).
For PA isolates from AZLI-treated patients, the MIC50 of
aztreonam increased from baseline to Day 14 (≤1 μg/mL to
4 μg/mL) as did the MIC90 (8 μg/mL to 32 μg/mL); these
increases were maintained at Days 28 and 42. For PA isolates
from placebo-treated patients, the MIC50 (≤1 μg/mL) and
MIC90 (16 μg/mL) of aztreonam remained unchanged during
the study.
The proportion of AZLI-treated patients who had PA isolates
with aztreonam MIC values N8 μg/mL (parenteral breakpoint)
increased from 9.4% at baseline (n=6/64) to 29.4% at Day 14
(n=15/51), and then remained fairly constant (Day 28: 26.5%,n=13/49; Day 42: 25.0%, n=15/60). The proportion of
placebo-treated patients who had PA isolates with aztreonam
MIC values N8 μg/mL remained fairly constant (baseline:
15.9%, n=10/63; Day 14: 20.3%, n=14/69, Day 28: 13.6%,
n=9/66; Day 42: 16.1%, n=10/62). The PA isolate that was
least susceptible to aztreonam was determined at baseline and at
Day 28 for each patient. A ≥4-fold increase in aztreonam MIC
for the least susceptible PA isolate was observed in 21 patients
(AZLI: 13; placebo: 8; Fig. 3). Of these 21 patients, 4 patients in
each treatment group had≥4-fold increases in MIC that crossed
or persisted above the aztreonam parenteral breakpoint of 8 μg/
mL. No relationship was observed between the magnitude of
the highest MIC of aztreonam for PA isolates for each patient at
baseline and mean changes in CFQ-R RSS scores, FEV1%
predicted, or log10 PA CFUs in sputum.
There was no evidence for persistent increases in the
isolation of Burkholderia spp., Stenotrophomonas maltophilia,
Achromobacter xylosoxidans, Aspergillus spp., or Staphyloc-
cous aureus.
4. Discussion
Patients treated with AZLI showed a modest improvement in
respiratory symptoms, as measured on the CFQ-R RSS. When
compared with placebo, the treatment effect was not clinically
or statistically significant, thus the study did not meet the
primary efficacy endpoint. A significant treatment effect was
observed at Day 28 for FEV1% predicted, a secondary endpoint.
This primarily resulted from a decrease from baseline at Day 28
for placebo-treated patients; a small improvement was observed
for AZLI-treated patients.
On the CFQ-R RSS, larger AZLI vs. placebo treatment
effects were observed for females compared with males, for
adults compared with children, for patients with highest
aztreonam MIC for PA N8 μg/mL compared with ≤8 μg/mL,
and for patients with FEV1b90% predicted at baseline
compared with ≥90% predicted, but none of these differences
were statistically significant. The larger treatment effects in
females and adults are in agreement with more compromised
lung function typically seen in these subgroups [3].
The FEV1% predicted treatment effect observed in this study
differed from the previously reported lack of significant lung
function treatment effect observed for a subset of patients with
baseline FEV1≥75% predicted in the placebo-controlled AZLI
Phase 2 study [15]. Lack of significant effects on lung function
were also reported in the literature for a placebo-controlled
study of tobramycin inhalation solution (TIS) in patients with
mild lung function impairment [16]. Further, significant
treatment effects were not observed for FEV1% predicted or
on the CFQ-R RSS in a recent hypertonic saline trial in patients
with FEV1N80% predicted [17]. The response of the placebo
group in the current study also differed from responses observed
in previous AZLI studies; in the current study both FEV1%
predicted and scores on the CFQ-R RSS improved in the
placebo group during the 14-day follow-up period and in
previous studies both remained unchanged or decreased [8,9].
The reason for this improvement in the placebo group is not
Table 2B
Efficacy results: additional endpoints.
Additional efficacy endpoints Placebo
(N=81)
AZLI
(N=76)
Treatment effect c P-value d
Adjusted mean change (SE) from baseline to Day 28
No. No.
Relative change in FEV1 (L)
a 81 −2.5 (0.83) 76 0.36 (0.85) 2.7 0.021
Relative change in FVC (L) a 81 −1.4 (0.71) 76 −0.04 (0.73) 1.4 0.171
Relative change in FEF25–75
a 81 −2.9 (2.2) 76 2.6 (2.3) 5.5 0.079
Relative change in weight a 81 −1.9 (1.3) 76 1.9 (1.3) 3.0 0.111
Change in BMI a (kg/m2) 81 −0.22 (0.24) 76 0.33 (0.24) 0.56 0.097
Change on CFQ-R Scales a,b
Body image 80 1.1 (1.6) 76 3.7 (1.7) 2.6 0.259
Digestion 81 5.5 (1.9) 75 3.6 (1.9) −1.9 0.470
Eating disturbances 81 −1.2 (1.5) 76 0.5 (1.5) −1.7 0.409
Emotional functioning 80 3.7 (1.2) 76 3.3 (1.2) −0.37 0.828
Health perceptions 54 −1.8 (2.0) 54 1.8 (2.0) 3.6 0.194
Role/school 55 1.2 (1.4) 53 0.29 (1.5) −0.90 0.650
Social functioning 80 −2.6 (1.3) 75 1.9 (1.4) 4.5 0.020
Treatment burden 81 5.1 (1.6) 76 1.2 (1.6) −3.9 0.075
Vitality 54 −2.2 (2.2) 54 0.38 (2.2) 2.6 0.402
Weight 55 2.6 (2.9) 53 4.3 (2.9) 1.7 0.667
Mean (SD)
Baseline to End of Study P-value e
Number Hospitalization Days 81 0.4 (2.5) 76 0.9 (3.1) 0.100
Number Missed School/Work Days 81 1.2 (3.0) 76 1.6 (4.9) 0.573
BMI=body mass index; CFQ-R=Cystic Fibrosis Questionnaire—Revised; FEF25–75= forced expiratory volume from 25% to 75% of FVC; FEV1=forced expiratory
volume in 1 s; FVC=forced vital capacity; PA=P. aeruginosa.
a Missing postbaseline data were imputed with the last observation carried forward (LOCF) method.
b CFQ-R Health Perceptions, Role/School, Vitality, and Weight scales have only an adolescent/adult version.
c AZLI — placebo.
d ANCOVA analyses. ANCOVA models included treatment, age group, and baseline values.
e Wilcoxon Rank Sum Test.
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additional inhaled antipseudomonal antibiotics during the
follow-up period as use of such antibiotics was similar for the
placebo and AZLI treatment groups.
AZLI was well tolerated, most adverse events were mild to
moderate in severity and the most commonly reported adverse
events were associated with respiratory symptoms.
In contrast to previously reported AZLI trials, including one of
18-month duration, there were slight increases in this study forTable 3
Adverse events reported for ≥10% of patients in either treatment group.
Preferred term Placebo
(N=81)
n (%)
AZLI
(N=76)
n (%)
P-value a
Cough 31 (38.3) 35 (46.1) 0.337
Productive cough 13 (16.0) 18 (23.7) 0.316
Nasal congestion 15 (18.5) 13 (17.1) 0.838
Headache 10 (12.3) 14 (18.4) 0.376
Oropharyngeal pain 11 (13.6) 12 (15.8) 0.822
Rhinorrhoea 12 (14.8) 8 (10.5) 0.479
Respiratory tract congestion 6 (7.4) 11 (14.5) 0.201
Fatigue 10 (12.3) 6 (7.9) 0.434
Pulmonary function test decreased 9 (11.1) 7 (9.2) 0.795
Diarrhea 9 (11.1) 3 (3.9) 0.133
Abdominal pain 10 (12.3) 1 (1.3) 0.010
a P-values are based on Fisher's Exact Test.MIC50 andMIC90 of aztreonam forPA afterAZLI treatment; these
increases suggest an element of inducible resistance [8–10]. This
interpretation is supported by the observation that the baseline
susceptibility ofPA isolates in this studywas generally greater than
in the previous studies and the observation that, formost patients in
this study, MIC values for PA isolates at Day 28 remained below
the aztreonam parenteral breakpoint. Patients in previous studies
had poorer lung function and were, on average, older than the
patients in the current study, and thus likely had a history of more
extensive treatment of PA airway infections. High aztreonam
MICs have not been predictive of lack of efficacy, presumably due
to the high aztreonam concentration achieved in sputum.
Since the CF medical community recognizes the importance
of preserving lung function in patients with chronic PA
infection, it is important to explore why a drug like AZLI did
not have a substantial treatment benefit on the CFQ-R RSS in
this study. It seems unlikely that AZLI does not benefit this
population; AZLI was effective in previous studies and there is
no pathophysiologic reason to believe that an effective
antibiotic would not benefit any CF population with chronic
PA infection. It is possible that the sensitivity of the CFQ-RSS is
not sufficient for patients with more modest symptoms at
baseline (ceiling effect) or that the study may not have been
adequately powered to detect a change. Sample size assump-
tions were based on observing a 10-point treatment difference
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was approximately 10 points higher than in previous AZLI
studies [8–10]. This indicates that patients in this study had
fewer symptoms at baseline, and coupled with their high
baseline FEV1% predicted values suggests that patients without
measurable compromise of lung function will not have
measurable improvement, in spite of chronic PA infection.
This hypothesis is supported by analyses of the patient subset
with FEV1N75 to b90% predicted; they had both measurable
compromise and measured benefit.
This study demonstrated a significant reduction in sputum
bacterial density and maintenance of FEV1% predicted in
AZLI-treated patients, compared with placebo. FEV1 has been
shown to decline in the placebo arm of other studies as well;
further supporting that maintenance of FEV1 should be a
meaningful outcome even in a short term study. In spite of the
general lack of demonstrated efficacy in patients with
FEV1N75% predicted, prescribing guidelines do not specify a
target level of lung compromise for azithromycin, hypertonic
saline, or dornase alfa, but are limited in the US to patients with
FEV1 25% to 75% predicted for TIS and AZLI.
While this study of AZLI in CF patients with mild lung
function impairment and airway PA did not meet its primary
endpoint, much has been learned about this population. AZLI
was well tolerated, FEV1% predicted declined in placebo-
treated patients even over the short course of this study, and PA
bacterial density decreased with AZLI treatment. In exploratory
analyses, patients with FEV1N75 to b90% predicted had
measurable improvement in respiratory symptoms and statisti-
cally significant improvements in FEV1% predicted, compared
to patients with FEV1≥90% predicted. Further studies of
antipseudomonal therapies such as AZLI are warranted in
patients with mild loss of lung function. Studies in patients with
FEV1N75 to b90% predicted may be able to use short-termclinical outcomes, but measuring responses in patients with
FEV1≥90% predicted likely will require trial designs that use
outcome measures that focus on the pathophysiology of the CF
airway disease, or may need long-term studies measuring
outcomes such as longitudinal decline in lung function.
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